Mild Cognitive Impairment Clinical Trial
Official title:
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
Verified date | December 2013 |
Source | Eisai Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).
Status | Completed |
Enrollment | 145 |
Est. completion date | September 2007 |
Est. primary completion date | September 2007 |
Accepts healthy volunteers | |
Gender | Both |
Age group | 45 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Age Range: Adult subjects (45 to 90 years of age inclusive) 2. Sex distribution: Men and women. Women of child-bearing potential (<1 year post menopausal) must be practicing effective contraception and have negative serum B-HCG at Screening. [Women who are breast-feeding are excluded.] 3. Subjects must have completed the one year, double-blind core trial (E2020-A001-412). 4. A completed Diagnostic Worksheet at the end of the double-blind core trial (E2020-A001-412) indicating no conversion to Alzheimer's Disease or dementia. 5. Health: Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane). 6. The subject must be expected to complete the entire study. 7. Subjects must be sufficiently fluent in English. 8. Subjects must have an informant who has daily contact with the subject (e.g., an average of 10 or more hours per week), can observe for possible adverse events and will accompany the subject to all visits. 9. Clinical laboratory values must be within normal limits, or if abnormal, judged clinically insignificant by the investigator (not likely to cause cognitive impairment or medical instability). Exclusion Criteria: 1. Subjects who have not completed or have terminated early from the one year, double-blind core trial (E2020-A001-412). 2. Any subject without a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412). 3. Any subject with a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412) indicating conversion to Alzheimer's or other dementia. 4. Subjects with uncontrolled hypertension (sitting systolic >= 160mmHg and/or diastolic >=95mmHg) as assessed by the investigator, regardless of whether or not the subject is taking anti-hypertensive medications. 5. Subjects with a history of malignant neoplasms treated within five years prior to study entry (other than basal or squamous cell carcinoma of the skin); current evidence of malignant neoplasm; or recurrent or matastatic disease. 6. Subjects who have suffered a severe infection or a major surgical procedure within three months prior to baseline. 7. Subjects who may not be able to comply with the protocol. 8. Subjects with known hypersensitivity to piperidine derivatives or acetylcholinesterase(AChE)inhibitors. 9. Subjects with diabetes mellitis not controlled by diet and/or medication with a random serum glucose value of >170mg/dl. 10. Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study. 11. Subjects who do not have a reliable informant (e.g., the informant has contact with the subject less than 10 hours per week). |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Neurology Neurodiagnostic Lab, LLC | Alabaster | Alabama |
United States | Neurological Associates of Albany, PC Neurology | Albany | New York |
United States | Clinical Trial Specialists | Bala Cynwyd | Pennsylvania |
United States | Southwestern Vermont Medical Center - The Memory Clinc | Bennington | Vermont |
United States | Medical University of South Carolina-Alzheimer's Research | Charleston | South Carolina |
United States | The Ohio State University | Columbus | Ohio |
United States | North Broward Medical Center Memory Disorder Center | Deerfield Beach | Florida |
United States | The Neurology Center | Encinitas | California |
United States | Margolin Brain Institute | Fresno | California |
United States | Neurologic Consultants | Ft. Lauderdale | Florida |
United States | Colaborative Neuroscience Network (CNS Network) | Garden Grove | California |
United States | Westmoreland Neurology Associates | Greensburg | Pennsylvania |
United States | Berma Research Group | Hialeah | Florida |
United States | Sunrise Clinical Research | Hollywood | Florida |
United States | The University of Texas Mental Sciences Instittute | Houston | Texas |
United States | Nerve Pro Research | Irvine | California |
United States | The Clinical Trial Center, LLC | Jenkintown | Pennsylvania |
United States | Borgess Research Institute | Kalamazoo | Michigan |
United States | Comprehensive Neuroscience, Inc | Kenilworth | New Jersey |
United States | Optimum Health Services | La Mesa | California |
United States | Neurobehavioral Research Inc. | Lawrence | New York |
United States | Lexington Clinic | Lexington | Kentucky |
United States | Wien Center for Memory Disorders, Mount Sinai Medical Center | Miami Beach | Florida |
United States | Yale University Alzheimers Disease Research Unit School of Medicine Department of Psychiatry | New Haven | Connecticut |
United States | Columbia University | New York | New York |
United States | New York University School of Medicine Aging and Dementia Research Center | New York | New York |
United States | Pahl Pharmaceutical Research, LLC | Oklahoma City | Oklahoma |
United States | Pivotal Research Centers | Peoria | Arizona |
United States | Berma Research Group | Plantation | Florida |
United States | Summit Research Network(Oregon) Inc. | Portland | Oregon |
United States | Monroe Community Hospital Program in Neurobehavioral Therapeutics | Rochester | New York |
United States | START Center | San Antonio | Texas |
United States | Pacific Research Network | San Diego | California |
United States | Neurological Research Institute | Santa Monica | California |
United States | The Roskamp Institute | Sarasota | Florida |
United States | CA Neuroscience Research | Sherman Oaks | California |
United States | St. Louis University - Clinical Trials Unit | St. Louis | Missouri |
United States | Comprehensive Neuroscience, Inc. | St. Petersburg | Florida |
United States | Behavioral Medical Research of Staten Island | Staten Island | New York |
United States | Sun Health Research Institute | Sun City | Arizona |
United States | Stedman Clinical Trials, LLC | Tampa | Florida |
United States | USF Memory Disorder's Clinic | Tampa | Florida |
United States | USF Suncoast Gerontalogy Center | Tampa | Florida |
United States | Neurology Center of Ohio | Toledo | Ohio |
United States | Northwest Neurospecialists, PLLC | Tucson | Arizona |
United States | Center for Clinical Trials. L.C. | Venice | Florida |
United States | Pacific Research Network | Vista | California |
United States | Palm Beach Neurology | West Palm Beach | Florida |
United States | Grayline Clinical Drug Trials | Wichita Falls | Texas |
Lead Sponsor | Collaborator |
---|---|
Eisai Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Treatment-Emergent Adverse Events | Overview of Treatment-Emergent Adverse Events and Safety Population (TEAEs) | Baseline, Week 6, Week 12 and Week 28. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |